Answers are grounded in this paper and cite their sources.
Respiratory Society classification of the idiopathic interstitial pneumonias [1] has redefined entities previously grouped as ''idiopathic pulmonary fibrosis'' (IPF), but carrying a much better prognosis than that disorder.As a result, the core entity of IPF is now diagnosed with greater precision than ever before.The outcome has worsened correspondingly, with an average survival of ,3 yrs from the onset of dyspnoea.Until recently, therapeutic nihilism in IPF has prevailed.Treatment recommendations have come and gone, high-dose corticosteroid therapy has had its day [2], and ''standard therapy'' has essentially failed.DEMEDTS et al. [3] recently reported outcome data that ought to encourage the optimists amongst us.For the first time, a widely available and inexpensive agent has effected a real difference in the rate of disease progression in a large cohort of patients.The methodology was straightforward.All patients remained on low-dose prednisolone and azathioprine throughout.The studied intervention consisted of the addition of Nacetylcysteine (NAC) at a dose of 600 mg t.i.d., controlled against placebo.There were differences in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DL,CO) at 12 months in favour of active treatment.With placebo, FVC and DL,CO fell 6 and 8% of predicted, respectively, but only 1.5 and 3% with active therapy.In other words, the rapidity of disease progression was curtailed by ,70% when antioxidant therapy was added to ''best current treatment''.
No takes yet. Share an insight, caveat, or question.
Athol U. Wells (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: